DEA, HHS extend telemedicine waivers through 2026

Dec 30, 2025 - 01:32 PM
A physician talks with a rural patient appearing on a laptop computer screen via a telehealth app.

The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver flexibilities for prescribing controlled substances via telemedicine. The waivers allow for the prescribing of schedule II-V controlled substances (including schedule III-V medications approved by the Food and Drug Administration for treatment of opioid use disorder) via audio-video telemedicine encounter without a prior in-person medical evaluation through Dec. 31, 2026. These flexibilities apply to all practitioner-patient relationships, not just those established during the COVID-19 public health emergency. The waivers were due to expire on Dec. 31, 2025; by extending them for another year, the agencies have additional time to develop and implement a permanent special registration process for prescribing of controlled substances.

Related News Articles

Headline
CMS says all states have applied for GENEROUS Model to provide most-favored-nation drug pricing
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
AHA podcast breaks down ‘phygital ecosystem’ on better patient care 
In this conversation, Jennifer Bollinger, chief consumer and brand officer at Sutter Health, discusses how a “phygital ecosystem” approach creates a seamless…
Headline
Webinar to explore how virtual nursing can impact patient flow
The AHA’s Hospital Capacity Management Consortium will host a webinar Aug. 12 at 1 p.m. ET on how virtual nursing models can improve hospital throughput,…
Headline
FDA announces actions to accelerate drug development 
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
HHS announces action plan on psychiatric ‘overprescribing’
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …
Headline
President’s EO speeds research, funding for psychedelic drug treatments
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…